Thomas H Taylor
Overview
Explore the profile of Thomas H Taylor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dayyani F, Chao J, Lee F, Taylor T, Neumann K, Cho M
Oncologist
. 2024 Jun;
29(8):721-e1088.
PMID: 38823034
Background: Most patients with metastatic gastroesophageal adenocarcinoma (mGEA) progress on immune checkpoint inhibitors (ICIs). Novel approaches to overcome resistance to ICI in mGEA are needed. Cabozantinib is a multi-tyrosine kinase...
2.
Dayyani F, Balangue J, Valerin J, Keating M, Zell J, Taylor T, et al.
Clin Colorectal Cancer
. 2023 Dec;
23(1):67-72.
PMID: 38103947
Introduction: This study determined the safety and recommended phase 2 dose (RP2D) of the multikinase inhibitor cabozantinib in combination with trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal carcinoma (mCRC). Patients And...
3.
Xia Y, Taylor T, Chen J, Hsia J
Arch Pathol Lab Med
. 2023 Jul;
148(4):443-452.
PMID: 37406294
Context.—: Two major categories of laboratories performing nonwaived testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) are the Certificate of Accreditation (CoA) and Certificate of Compliance (CoC) laboratories....
4.
Zell J, Taylor T, Albers C, Carmichael J, McLaren C, Wenzel L, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046763
After potentially curative treatment, colorectal cancer (CRC) patients remain at high risk for recurrence, second primary CRC, and high-risk adenomas. In combination with existing data, our previous findings provide a...
5.
Bota D, Taylor T, Piccioni D, Duma C, LaRocca R, Kesari S, et al.
J Exp Clin Cancer Res
. 2022 Dec;
41(1):344.
PMID: 36517865
Background: Vaccine immunotherapy may improve survival in Glioblastoma (GBM). A multicenter phase II trial was designed to determine: (1) the success rate of manufacturing the Aivita GBM vaccine (AV-GBM-1), (2)...
6.
Silberman J, Sarlati S, Harris B, Bokhari W, Boushey H, Chesnutt A, et al.
Contemp Clin Trials
. 2022 Sep;
122:106902.
PMID: 36049674
Asthma self-management can improve symptom control, but adherence to established self-management behaviors is often poor. With adult asthma uncontrolled in over 60% of U.S. cases, there is a need for...
7.
8.
Bota D, Taylor T, Lomeli N, Kong X, Fu B, Schonthal A, et al.
Front Oncol
. 2022 Jul;
12:934638.
PMID: 35837107
Background: Glioblastoma (GBM) is the most common primary, malignant brain tumor in adults and has a poor prognosis. The median progression-free survival (mPFS) of newly diagnosed GBM is approximately 6...
9.
Dayyani F, Smith B, Nguyen N, Daly S, Hinojosa M, Seyedin S, et al.
Future Oncol
. 2022 May;
18(21):2615-2622.
PMID: 35603628
Current guidelines recommend neoadjuvant (NAC) and/or adjuvant chemotherapy for locally advanced gastric cancers (LAGCs). However, the choice and duration of NAC regimen is standardized, rather than personalized to biologic response,...
10.
Dayyani F, Tam K, Kim E, Ejadi S, Valerin J, Taylor T, et al.
Med Oncol
. 2022 May;
39(5):102.
PMID: 35599264
TAS-102 is approved for treatment of refractory metastatic gastroesophageal carcinoma (mGEC). This study sought to determine whether the combination of TAS-102 with irinotecan (TASIRI) was safe and effective in previously...